Clinical trial · Interventional
Phase IIT Trial of SNA014
Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer
NCT06646783CI-TRIAL-00081712not yet recruitingEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of GE Junction | — | UNRESOLVED | — |
| Adenocarcinoma of the Stomach | Gastric Adenocarcinoma | ALIAS | 0.90 |
| Pancreatic Cancer Stage | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [68Ga]Ga-NODAGA-SNA014 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- dose escalation
- description
- subgroups mass does escalation
- interventionNames
- Drug: [68Ga]Ga-NODAGA-SNA014
Primary outcomes (2)
- measure
- Biological distribution characteristics
- timeFrame
- 1week
- description
- Evaluate the biological distribution characteristics of important organs in the subjects. * Draw the Volume of Interest (VOI) of the subject's vital organs and calculate the Percentage of Injected Activity (IA) of the vital organs * Using PMOD software, manually draw regions of interest (VOI) on PET/CT images of the liver, spleen, normal stomach, heart, bone marrow, kidneys, and other areas to obtain the cumulative radioactive activity of these regions. Divide the cumulative radioactive activity by the injection dose to obtain the percentage of injection activity (% IA).
- measure
- Safety tolerance characteristics
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age range of 18 to 75 years old (including boundary values); * Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF); * Diagnosed G/GEJ adenocarcinoma and pancreatic cancer; * Gastroscopy/CT/MRI/PET-CT examination results within the past month (if any); * Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available). Exclusion Criteria: * Merge patients with other clearly diagnosed malignant tumors: * Uncontrolled severe infections or individuals with other serious illnesses; * Those with an expected survival period of less than or equal to three months; * Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial; * investigators determine that patients who are not suitable to participate in this study;
References
Publications (0)
Data not yet available
No reference posted for this study.